Convertible Notes vs. SAFE Agreements: A Practical Guide for Angel Investors

If you've made more than a handful of angel investments, you've probably signed both convertible notes and SAFEs without fully understanding the differences between them. Don't feel bad — the nuances are genuinely confusing, and most educational content on the topic reads like it was written by a securities lawyer trying to impress other securities lawyers.

We're going to fix that. This is the practical, investor-centric guide to convertible notes and SAFEs that we wish someone had written for us when we started angel investing.

Let's start with what these instruments have in common, because that's where most of the confusion begins.

The Shared DNA: Why These Instruments Exist

Both convertible notes and SAFEs exist to solve the same problem: pricing a startup is really hard at the seed stage, and negotiating a full priced equity round is expensive, time-consuming, and often impractical.

In a priced equity round, you negotiate a specific valuation, purchase shares at a specific price, and receive a defined ownership percentage. This works well when there's enough information to support a credible valuation — revenue, comparable transactions, competitive bids from multiple investors.

At the seed stage, most of that information doesn't exist. The startup may be pre-revenue, pre-product, or even pre-team. Trying to agree on a specific valuation is an exercise in collective fiction. And the legal costs of a priced round ($15,000–50,000 for a seed deal) can eat a meaningful percentage of a small raise.

Convertible instruments solve this by deferring the valuation question. Instead of pricing the company today, you invest money today and receive equity later — typically when the company raises a subsequent priced round (a Series A, usually). Your conversion terms determine how many shares you receive and at what price.

Both convertible notes and SAFEs accomplish this deferral, but they do it differently, and those differences matter more than most angels realize.

Convertible Notes: The Original

A convertible note is a loan. Specifically, it's a short-term debt instrument that converts into equity upon a triggering event (usually a qualified financing round). Because it's debt, it has features that equity instruments don't:

Interest rate. Convertible notes accrue interest, typically at 4–8% annually. The accrued interest converts into additional equity at conversion, effectively giving the noteholder a slightly larger ownership stake. Interest rates on convertible notes are largely standardized and rarely a point of negotiation.

Maturity date. As a loan, a convertible note has a repayment deadline — typically 18–24 months after issuance. If the note hasn't converted by the maturity date, the investor theoretically has the right to demand repayment. In practice, this rarely happens because demanding repayment from a cash-strapped startup is both impractical and counterproductive.

Valuation cap. The cap sets a maximum valuation at which the note will convert. If the Series A values the company at $20 million but your note has a $10 million cap, your note converts at the $10 million valuation, giving you twice as many shares as you'd get at the Series A price.

Discount. The discount gives the noteholder a percentage reduction from the Series A price, typically 15–25%. If the Series A price is $1.00 per share and your note has a 20% discount, you convert at $0.80 per share.

Notes typically convert at the better of the cap or the discount — meaning you get whichever one gives you more shares.

SAFEs: Y Combinator's Innovation

The SAFE (Simple Agreement for Future Equity) was created by Y Combinator in 2013 to address what they saw as unnecessary complexity in convertible notes. It's not debt — it's a contractual right to receive equity upon a triggering event.

Because it's not debt, a SAFE has no interest rate and no maturity date. It's a simpler instrument by design. A standard SAFE is 5–6 pages long, compared to 8–15 pages for a typical convertible note.

Like convertible notes, SAFEs use valuation caps and discounts to determine conversion terms. The current standard (the "post-money SAFE," introduced by Y Combinator in 2018) specifies that the valuation cap is a post-money valuation, which means the investor can calculate their exact ownership percentage at the time of investment, assuming no subsequent dilution before the conversion event.

The Key Differences (And Why They Matter to You)

1. Debt vs. Equity: More Than Semantics

The debt vs. equity distinction has several practical implications:

In a liquidation scenario (the company sells or shuts down before the note converts): Convertible noteholders are creditors. They get paid before equity holders, including founders. If the company sells for $5 million and has $1 million in convertible notes outstanding, the noteholders get their $1 million back (plus accrued interest) before the equity holders divide the remaining $4 million.

SAFE holders are not creditors. In a liquidation, they receive the greater of (a) their original investment amount or (b) the amount they would have received if the SAFE had converted at the cap. But they're paid from the same pool as other equity holders, which means in a low-value exit, they may receive less than noteholders would.

This matters more than most angels realize. The majority of startup exits are small acquisitions, acqui-hires, and wind-downs — scenarios where the liquidation preference determines whether you get your money back. Convertible notes provide stronger protection in these scenarios.

2. The Maturity Date: Leverage or Liability?

Convertible notes have maturity dates. SAFEs don't. This difference cuts both ways.

For the investor, a maturity date provides leverage. If the company hasn't raised a qualifying round or achieved meaningful progress by the maturity date, the investor can (theoretically) demand repayment or negotiate more favorable conversion terms. The maturity date is a forcing function that prevents the company from using your money indefinitely without triggering conversion.

Against the investor, a maturity date creates administrative complexity. When notes mature, someone needs to decide what to do — extend the note, convert it, negotiate new terms, or pursue repayment. Most notes are simply extended, but the negotiation around extension can be awkward, time-consuming, and occasionally contentious.

SAFEs avoid this entirely. With no maturity date, the SAFE simply sits on the company's balance sheet until a conversion event occurs. This is simpler, but it also means the investor has no built-in mechanism to force a resolution if the company perpetually avoids raising a priced round.

Our view: For most angel investments, the maturity date is a modest advantage. Not because you'll ever actually demand repayment, but because it creates a natural checkpoint for evaluating the company's progress and having a candid conversation with the founders.

3. Pre-Money vs. Post-Money Caps

This is the most important technical distinction, and it's the one that most commonly catches angel investors off guard.

Convertible notes traditionally use pre-money valuation caps. If your note has a $10 million cap and the company raises a $2 million Series A, the effective post-money valuation for your conversion is $12 million ($10 million pre-money + $2 million new money). If multiple noteholders have caps, they all convert at the same pre-money cap, and the total dilution to founders depends on the total amount of notes outstanding.

Post-money SAFEs use post-money valuation caps. If your SAFE has a $10 million post-money cap and you invested $500,000, you own exactly 5% of the company at conversion ($500,000 / $10 million). But here's the critical wrinkle: if other SAFE holders also have $10 million post-money caps, each of you owns your pro-rata percentage based on the $10 million cap, and the total dilution to founders increases with each additional SAFE.

Why this matters: With pre-money caps, additional investors at the same cap don't change your ownership percentage — they dilute the founders. With post-money caps, your ownership percentage is fixed, and additional investors dilute the founders more. From the founder's perspective, post-money SAFEs are more transparent (each investor knows exactly what they'll own) but potentially more dilutive. From the investor's perspective, post-money SAFEs provide certainty of ownership, which is valuable.

Make sure you understand which type of cap you're getting. And if a founder offers you a SAFE with a pre-money cap (some do, using older SAFE templates), ask them to clarify whether they mean pre-money or post-money, because the difference can be substantial.

4. Pro-Rata Rights

Pro-rata rights — the right to invest in future rounds to maintain your ownership percentage — are handled differently by the two instruments.

Convertible notes sometimes include pro-rata rights, but they vary by negotiation. SAFEs (the standard Y Combinator version) include a separate "Pro-Rata Side Letter" that grants the investor the right to participate in the next equity financing round.

Our view: Pro-rata rights are valuable and you should negotiate for them regardless of which instrument you use. The ability to double down on your winners is one of the key drivers of angel investing returns. For more on why this matters, see our guide to portfolio diversification.

Which Should You Prefer?

Here's our opinionated take:

For most angel investments, we slightly prefer convertible notes. The debt status provides better protection in liquidation scenarios, the maturity date provides a natural checkpoint, and the interest accrual (while modest) provides a small additional return. The added complexity relative to SAFEs is manageable and well understood by startup attorneys.

However, SAFEs are perfectly acceptable and have become the market standard for Y Combinator companies and many other startups. If a founder insists on using a SAFE, that's not a dealbreaker — just make sure it's the standard post-money SAFE, that the cap is reasonable, and that you have pro-rata rights.

What you should never accept: A SAFE with no cap and no discount. This instrument gives the company a free option on your money with no guaranteed terms. You're betting entirely on the company's future fundraising valuation, which gives the founders every incentive to raise the next round at the highest possible valuation — great for them, potentially terrible for you.

If a founder tells you that their company is "too early to price" but also too hot for you to negotiate a cap, you should politely decline. The whole point of a cap is to compensate you for the risk you're taking by investing before the company has proven itself.

For a broader look at common mistakes new angels make — including deal structure errors — see our guide for first-time investors.

Negotiation Tips for Both Instruments

Regardless of which instrument you use, here are the terms worth negotiating:

1. Valuation cap: This is the most important term. It should reflect the company's current stage and traction, not its aspirational future valuation. At seed stage, caps typically range from $5–20 million for most startups (higher for AI and other hot sectors, as we've discussed elsewhere).

2. Discount: Standard is 20%. Some investors negotiate 25% for very early deals. Below 15% isn't worth the ink.

3. Pro-rata rights: Always ask. Founders who refuse pro-rata rights to seed investors are raising a yellow flag about how they'll treat early supporters.

4. Information rights: The right to receive regular financial updates (quarterly P&L, annual balance sheet, cap table updates). Not always included in standard templates but worth requesting.

5. Most Favored Nation (MFN) clause: If the company issues subsequent convertible instruments on better terms, the MFN clause gives you the right to adopt those terms. Standard in SAFEs, sometimes negotiated in notes.

The Bottom Line

Convertible notes and SAFEs are tools, not religions. The best instrument for a specific deal depends on the specific circumstances — the company's stage, the amount being raised, the number of investors, the founder's preferences, and the market dynamics.

What matters most is not which instrument you use but whether the terms are fair, the cap is reasonable, and your rights as an investor are protected. Focus on those fundamentals, and the choice between notes and SAFEs becomes a secondary consideration.

---

Need help evaluating a specific deal structure? AIN members can submit deal terms for review by our community of experienced angels. Join the network.